More Than a Biobank: The Crohn's & Colitis Foundation Partners with Brooks Life Sciences

The role of a biobank in the drug discovery process has advanced over the past 10 years. In an interview with Mary Ann Brown on behalf of Bio-IT World, Dr. Andy Brooks, COO at RUCDR Infinite Biologics and Professor of Genetics at Rutgers University, explained this evolution.


“I think the single biggest change [in biobanking] over the last 10 years is the role of the biobank. It has evolved from, ‘we'll take care of your samples in these freezers at these controlled environments and make sure nothing happens to them,’ to a critical and pivotal role in the engagement of sample collection, the processing of samples, the quality control of those samples, the management of that data, and actually managing that kind of shared resource that's being developed – versus just a central area for where you keep and how we manage the samples.”

He continued, “I think that's continuing to change. As biobanking makes a transition into healthcare and clinical care, that role will continue to evolve, where the lines between the collection, testing, and storage of those samples will ultimately all become part of a biorepository framework.”

More than a biobank: Crohn’s & Colitis Foundation chooses Brooks Life Sciences to store samples for precision medicine research
Nearly 3.1 million Americans live with Inflammatory Bowel Disease (IBD). The Crohn’s & Colitis Foundation is committed to bringing together IBD patients to engage in the research and discovery process of fighting against Crohn’s and colitis. As with many pharma and biotech companies, the Crohn’s & Colitis Foundation needed to grow strategic partnerships to improve the complexity of managing samples and allow more efficiency in the overall R&D process. They needed a partner with an unblemished record who could oversee the sample management process, including (but not limited to) safely moving and relocating samples.

They were searching for a biobank that was more than a biobank. Brooks answered the call.
Angela Dobes, Senior Director of IBD Plexus for the Crohn’s & Colitis Foundation explains. “Their working knowledge of sample collection, storage, and management was clear. Their best-in-class capabilities and skills also carry over into sample processing, such as extracting DNA from the blood.”

Download the feature story below – and learn how Brooks is partnering with pharma and biotech companies to improve their end-to-end sample management process, so they can focus on bringing life-changing treatments to market.